Fisher & Paykel Healthcare Corp Ltd shares plunge: Is it a bargain?

Fisher & Paykel Healthcare Corp Ltd (ASX:FPH) shares plunge on a downgrade. But should you buy the dip?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of the worst performers on the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) today has been Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) with a 6% drop to $7.84.

It would appear as though today's decline is the result of a downgrade to a hold rating from analysts at Deutsche Bank.

A research note out of the investment bank reveals that despite yesterday's record half-year result from the leading provider of respiratory care medical devices, its analysts have concerns over the ongoing legal battle with rival ResMed Inc. (CHESS) (ASX: RMD).

In August Fisher & Paykel Healthcare alleged that a number of ResMed products infringe on its patents. ResMed responded by filing their own complaint of patent infringement against Fisher & Paykel Healthcare.

Fisher & Paykel responded by stating that:

"Fisher & Paykel Healthcare has been providing unique solutions for patients suffering from OSA for more than 20 years and we take pride in our proprietary technology, having built a significant patent portfolio over the past 20 years. We also respect the valid intellectual property rights of others, and we are confident in our position with respect to ResMed's patents given the rigorous clearance we conduct before any product is released to market."

Neither company has updated the market since, but it would seem as though Deutsche Bank isn't overly confident in the outcome of the court proceedings.

But another investment bank doesn't have any concerns. Analysts at Citi have labelled Fisher & Paykel Healthcare a buy today after its half-year results outperformed their expectations.

For the first half of FY 2017 the company reported a 12% increase in operating revenue to NZ$425.2 million. The bottom line performance was even stronger with net profit after tax up 26% to a record NZ$78.2 million.

In light of this management upgraded its full year earnings guidance to be in the range of NZ$165 million to NZ$170 million. Up between 15% and 19.5% on last year's NZ$143.4 million.

At 25x estimated FY 2017's earnings Fisher & Paykel Healthcare could be great value now considering its performance and the strong growth potential for the obstructive sleep apnea market.

However, investors may want to err on the side of caution and wait for the patent disputes to resolve before investing.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »